CDRT15L1 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the CDRT15-Like 1 (CDRT15L1) protein, a relatively lesser-known member of the broader protein family involved in cellular regulation and signaling. CDRT15L1 is thought to play a role in the intricate processes of cell communication and structural organization within various tissues. It may also participate in regulatory networks related to cellular adhesion, migration, and interaction. Inhibitors of CDRT15L1 are developed to interfere with the protein's function by binding to specific active sites or regions critical for its interaction with other cellular components. This disruption can shed light on the specific contributions of CDRT15L1 to cellular architecture and signal transmission.
The inhibition of CDRT15L1 may affect processes that involve the maintenance of cellular junctions and the organization of cellular networks, particularly in tissues where CDRT15L1 is expressed. By blocking its activity, CDRT15L1 inhibitors can help identify its functional role in the modulation of cell adhesion and intracellular signaling pathways. Structurally, these inhibitors are designed to interfere with key domains of CDRT15L1 that are essential for its interaction with other proteins, thus altering its capacity to contribute to cellular dynamics. This class of inhibitors serves as an important tool for researchers seeking to dissect the molecular pathways in which CDRT15L1 is involved, as well as to better understand the structural and biochemical mechanisms that govern its role in cellular processes. By studying these inhibitors, researchers can explore the specific biological functions of CDRT15L1 in various contexts, including tissue organization and cellular communication.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibitor of PI3K, could interrupt PI3K/Akt signaling and thereby impact CDRT15L1 if it relies on this pathway for activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor, could prevent activation of the MAPK/ERK pathway, potentially affecting CDRT15L1 if it is regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, could disrupt JNK signaling potentially involved in CDRT15L1's function or regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor, could alter stress response pathways that might modulate CDRT15L1 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor, could impact signaling pathways that CDRT15L1 may be a part of if it is downstream of EGFR. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF kinase inhibitor, could inhibit pathways upstream of ERK/MAPK signaling that may affect CDRT15L1. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor, could non-selectively inhibit kinases that phosphorylate CDRT15L1 or regulate its activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL tyrosine kinase inhibitor, could affect CDRT15L1 if it is involved in signaling pathways affected by BCR-ABL. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which could disrupt the mTOR signaling pathway potentially involving CDRT15L1. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Inhibits the Hedgehog signaling pathway, which could affect CDRT15L1 if it is part of this pathway's regulatory network. | ||||||